Follow The Filings

INTS Intensity Therapeutics

Intensity Therapeutics earnings company data as of 7:50 PM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by INTS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All INTS insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales

No open-market buys or sales on file.

Also filed in the last 12 months, not counted as buying or selling: 5 stock grants.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
10-Q
8-K 2.02,9.01
8-K 5.07
10-Q
8-K 2.02,9.01
DEF 14A
DEFA14A
10-K
8-K 2.02,9.01
424B5
8-K 8.01,9.01
8-K 8.01,9.01
8-K 2.02,9.01
8-K 3.03,5.03,8.01,9.01
8-K 3.01,9.01
424B5
8-K 8.01,9.01
10-Q
8-K 2.02,9.01
424B5
8-K 1.01,8.01,9.01
8-K 5.07
8-K 8.01
DEF 14A
DEFA14A

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.